LM Advisors LLC Acquires Shares of 22,242 Pfizer Inc. (NYSE:PFE)

LM Advisors LLC acquired a new stake in Pfizer Inc. (NYSE:PFE) during the 4th quarter, HoldingsChannel.com reports. The institutional investor acquired 22,242 shares of the biopharmaceutical company’s stock, valued at approximately $640,000.

Several other institutional investors also recently bought and sold shares of PFE. GoalVest Advisory LLC lifted its position in Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 811 shares in the last quarter. VisionPoint Advisory Group LLC lifted its position in Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 1,047 shares in the last quarter. Tennessee Valley Asset Management Partners purchased a new position in Pfizer during the fourth quarter worth approximately $36,000. DiNuzzo Private Wealth Inc. purchased a new position in Pfizer during the fourth quarter worth approximately $37,000. Finally, Life Planning Partners Inc purchased a new position in Pfizer during the fourth quarter worth approximately $39,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages recently commented on PFE. Guggenheim began coverage on Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Monday, April 15th. BMO Capital Markets restated an “outperform” rating and issued a $36.00 target price (up previously from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, Morgan Stanley lifted their target price on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research report on Thursday, May 2nd. Ten research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $35.86.

Pfizer Stock Down 0.1 %

PFE traded down $0.03 on Tuesday, hitting $28.04. 29,563,530 shares of the company were exchanged, compared to its average volume of 41,761,305. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $40.37. The company has a market cap of $158.89 billion, a price-to-earnings ratio of -467.26, a price-to-earnings-growth ratio of 1.12 and a beta of 0.70. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66. The firm has a 50-day moving average price of $27.52 and a two-hundred day moving average price of $27.81.

Pfizer (NYSE:PFE) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, topping the consensus estimate of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The firm had revenue of $14.88 billion during the quarter, compared to analysts’ expectations of $13.87 billion. During the same period in the previous year, the firm posted $1.23 EPS. Pfizer’s revenue for the quarter was down 19.5% on a year-over-year basis. On average, equities analysts predict that Pfizer Inc. will post 2.38 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be paid a dividend of $0.42 per share. The ex-dividend date is Thursday, May 9th. This represents a $1.68 annualized dividend and a yield of 5.99%. Pfizer’s payout ratio is -2,799.53%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.